UPB
Upstream Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.01
−1.15%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$329.17M
MomentumView details →
1D Return
−1.15%
YTD Return
−77.62%
RSI (14)
37.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$329.17M
RSI (14)
37.4
MomentumView details →
1D Return
−1.15%
YTD Return
−77.62%
SummaryUpdated Jun 1, 2026
Upstream Bio, Inc. (NASDAQ:UPB) is a clinical-stage biotechnology company founded in 2021 and headquartered in Waltham, Massachusetts. The company focuses on developing innovative treatments for inflammatory diseases, particularly severe respiratory disorders. Since its incorporation, Upstream Bio has positioned itself as a specialized player in the competitive biotechnology landscape, concentrating its research and development efforts on targeting specific inflammatory pathways that contribute to debilitating respiratory conditions.
Similar companies
Latest newsMore news →
Upstream Bio announced pivotal Phase 3 development plans for verekitug in severe asthma and CRSwNP, with trials to start in Q1 2027.3d agoUpstream Bio, Inc. reported a second-quarter net loss of $0.73 per share, narrower than the Zacks Consensus Estimate of a $0.78 loss and slightly improved from a $0.74 loss a year earlier.24d ago